...
search icon
bbio-img

BridgeBio Pharma Inc, Common Stock

BBIO

NSQ

$33.87

+$0.02

(0.06%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.45B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$21.62 L
$39.47 H
$33.87

About BridgeBio Pharma Inc, Common Stock

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBBIOSectorS&P500
1-Week Return4.83%0.44%0.24%
1-Month Return2.61%-7.69%-7.32%
3-Month Return0.24%-3.35%-12.05%
6-Month Return29.32%-11.09%-9.73%
1-Year Return35.59%-2.13%5.05%
3-Year Return231.73%-1.18%20.03%
5-Year Return23.66%34.44%83.31%
10-Year Return22.94%84.87%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue8.25M69.72M77.65M9.30M221.90M[{"date":"2020-12-31","value":3.72,"profit":true},{"date":"2021-12-31","value":31.42,"profit":true},{"date":"2022-12-31","value":34.99,"profit":true},{"date":"2023-12-31","value":4.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue3.09M3.11M3.43M2.45M3.88M[{"date":"2020-12-31","value":79.63,"profit":true},{"date":"2021-12-31","value":80.3,"profit":true},{"date":"2022-12-31","value":88.55,"profit":true},{"date":"2023-12-31","value":63.07,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit5.16M66.60M74.21M6.86M218.02M[{"date":"2020-12-31","value":2.37,"profit":true},{"date":"2021-12-31","value":30.55,"profit":true},{"date":"2022-12-31","value":34.04,"profit":true},{"date":"2023-12-31","value":3.15,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin62.57%95.53%95.58%73.71%98.25%[{"date":"2020-12-31","value":63.68,"profit":true},{"date":"2021-12-31","value":97.23,"profit":true},{"date":"2022-12-31","value":97.28,"profit":true},{"date":"2023-12-31","value":75.02,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses482.73M646.35M546.09M614.23M811.00M[{"date":"2020-12-31","value":59.52,"profit":true},{"date":"2021-12-31","value":79.7,"profit":true},{"date":"2022-12-31","value":67.34,"profit":true},{"date":"2023-12-31","value":75.74,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(474.48M)(579.75M)(471.87M)(607.37M)(592.97M)[{"date":"2020-12-31","value":-47448200000,"profit":false},{"date":"2021-12-31","value":-57974600000,"profit":false},{"date":"2022-12-31","value":-47187100000,"profit":false},{"date":"2023-12-31","value":-60737000000,"profit":false},{"date":"2024-12-31","value":-59297300000,"profit":false}]
Total Non-Operating Income/Expense(63.65M)(55.47M)(45.35M)(109.13M)(31.26M)[{"date":"2020-12-31","value":-6364600000,"profit":false},{"date":"2021-12-31","value":-5546700000,"profit":false},{"date":"2022-12-31","value":-4534600000,"profit":false},{"date":"2023-12-31","value":-10913200000,"profit":false},{"date":"2024-12-31","value":-3126200000,"profit":false}]
Pre-Tax Income(505.49M)(586.45M)(484.65M)(653.25M)(542.19M)[{"date":"2020-12-31","value":-50548800000,"profit":false},{"date":"2021-12-31","value":-58645400000,"profit":false},{"date":"2022-12-31","value":-48465200000,"profit":false},{"date":"2023-12-31","value":-65325100000,"profit":false},{"date":"2024-12-31","value":-54219400000,"profit":false}]
Income Taxes(21.56M)52.84M9.31M71.51M1.15M[{"date":"2020-12-31","value":-30.15,"profit":false},{"date":"2021-12-31","value":73.9,"profit":true},{"date":"2022-12-31","value":13.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":1.61,"profit":true}]
Income After Taxes(483.93M)(639.30M)(493.96M)(724.76M)(543.35M)[{"date":"2020-12-31","value":-48392500000,"profit":false},{"date":"2021-12-31","value":-63929700000,"profit":false},{"date":"2022-12-31","value":-49396400000,"profit":false},{"date":"2023-12-31","value":-72476100000,"profit":false},{"date":"2024-12-31","value":-54334700000,"profit":false}]
Income From Continuous Operations(505.49M)(586.45M)(484.65M)(653.25M)(543.35M)[{"date":"2020-12-31","value":-50548800000,"profit":false},{"date":"2021-12-31","value":-58645400000,"profit":false},{"date":"2022-12-31","value":-48465200000,"profit":false},{"date":"2023-12-31","value":-65325100000,"profit":false},{"date":"2024-12-31","value":-54334700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(483.93M)(639.30M)(493.96M)(643.20M)(535.76M)[{"date":"2020-12-31","value":-48392500000,"profit":false},{"date":"2021-12-31","value":-63929700000,"profit":false},{"date":"2022-12-31","value":-49396400000,"profit":false},{"date":"2023-12-31","value":-64320200000,"profit":false},{"date":"2024-12-31","value":-53576200000,"profit":false}]
EPS (Diluted)(3.80)(3.91)(3.11)(3.94)(2.82)[{"date":"2020-12-31","value":-380,"profit":false},{"date":"2021-12-31","value":-391,"profit":false},{"date":"2022-12-31","value":-311,"profit":false},{"date":"2023-12-31","value":-394,"profit":false},{"date":"2024-12-31","value":-282.4,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BBIO
Cash Ratio 16.48
Current Ratio 17.44

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BBIO
ROA (LTM) -47.83%
ROE (LTM) -1789.67%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BBIO
Debt Ratio Lower is generally better. Negative is bad. 2.59
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.60

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BBIO
Trailing PE NM
Forward PE NM
P/S (TTM) 29.03
P/B 123.68
Price/FCF NM
EV/R 33.76
EV/Ebitda NM

FAQs

What is BridgeBio Pharma Inc share price today?

BridgeBio Pharma Inc (BBIO) share price today is $33.87

Can Indians buy BridgeBio Pharma Inc shares?

Yes, Indians can buy shares of BridgeBio Pharma Inc (BBIO) on Vested. To buy BridgeBio Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BBIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BridgeBio Pharma Inc be purchased?

Yes, you can purchase fractional shares of BridgeBio Pharma Inc (BBIO) via the Vested app. You can start investing in BridgeBio Pharma Inc (BBIO) with a minimum investment of $1.

How to invest in BridgeBio Pharma Inc shares from India?

You can invest in shares of BridgeBio Pharma Inc (BBIO) via Vested in three simple steps:

  • Click on Sign Up or Invest in BBIO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BridgeBio Pharma Inc shares
What is BridgeBio Pharma Inc 52-week high and low stock price?

The 52-week high price of BridgeBio Pharma Inc (BBIO) is $39.47. The 52-week low price of BridgeBio Pharma Inc (BBIO) is $21.62.

What is BridgeBio Pharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BridgeBio Pharma Inc (BBIO) is 123.68

What is the Market Cap of BridgeBio Pharma Inc?

The market capitalization of BridgeBio Pharma Inc (BBIO) is $6.45B

What is BridgeBio Pharma Inc’s stock symbol?

The stock symbol (or ticker) of BridgeBio Pharma Inc is BBIO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top